/Intuitive%20Surgical%20Inc%20location%20sign-by%20Sundry%20Photography%20via%20iStock.jpg)
Sunnyvale, California-based Intuitive Surgical, Inc. (ISRG) develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care. Valued at $133.1 billion by market cap, the company offers endoscopes, endoscopic retractors and disectors, scissors, scalpels, forceps, needle holders, electrocautery, ultrasonic cutters, and accessories during surgical procedures.
Companies worth $10 billion or more are generally described as “large-cap stocks,” and ISRG definitely fits that description, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the medical instruments & supplies industry. Intuitive Surgical excels in robotic-assisted surgery with its gold-standard da Vinci system, backed by strong brand reputation, continuous R&D investment, and comprehensive surgeon training, driving user proficiency and patient outcomes.
Despite its notable strength, ISRG slipped 39.1% from its 52-week high of $603.88, achieved on Jan. 7. Over the past three months, ISRG stock declined 9.3%, underperforming the State Street SPDR S&P Health Care Equipment ETF’s (XHE) 19.5% gains during the same time frame.
Shares of ISRG fell 34% on a YTD basis and dipped 21% over the past 52 weeks, notably underperforming XHE’s YTD gains of 7.7% and 16% returns over the last year.
To confirm the bearish trend, ISRG has been trading below its 50-day moving average since mid-January, with some fluctuations. The stock has been trading below its 200-day moving average since late January.
Despite reporting solid underlying revenue and procedure volume growth, ISRG has underperformed over the past year primarily due to tight hospital capital budgets and emerging competition from rival robotic systems. Investors are particularly concerned that changes to Affordable Care Act (ACA) exchange coverage could weigh on elective procedure volumes. These regulatory shifts have forced ISRG into a conservative posture, signaling a potential moderation in procedure-driven instrument demand over the near term.
In the competitive arena of medical instruments & supplies, Cooper Companies, Inc. (COO) has taken the lead over the stock, with a 14.2% loss on a YTD basis and a 4.4% uptick over the past 52 weeks.
Wall Street analysts are bullish on ISRG’s prospects. The stock has a consensus “Strong Buy” rating from the 31 analysts covering it, and the mean price target of $483.34 suggests a potential upside of 31.5% from current price levels.
